Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Eyenovia, Inc.
Sponsors are receiving information requests and complete response letters as a result of the agency’s transition plan, which was made in response to the Genus v. FDA ruling. The decision's aftershocks could reshape the landscape for a number of products, attorney says.
Keeping Track: A Lawsuit-Driven Complete Response Letter, A Refuse To File Letter, And Some Good News
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
AbbVie had no presence in ophthalmic medicine other than a single indication for Humira before the Allergan merger, but now has a growing eye care portfolio, including early FDA approval of Vuity for presbyopia.
News and highlights of applications submitted for US FDA approval, from the Pink Sheet’s FDA Performance Tracker
- Medical Devices
- Drug Delivery
- Specialty Pharmaceuticals
- Site Specific
- Other Names / Subsidiaries
- PGP Holdings V, Inc.